Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lanoteplase.

N Bhana1, C M Spencer

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 24, 2007
PubMed
Summary
This summary is machine-generated.

Lanoteplase, a thrombolytic drug, effectively restored blood flow in acute myocardial infarction patients. It demonstrated comparable efficacy to alteplase in reducing mortality, with a trend towards fewer adverse events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quetiapine : A Review of its Use in Schizophrenia.

CNS drugs·2016
Same author

The Yin and Yang of inflammation.

Current molecular medicine·2014
Same author

Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells.

Mucosal immunology·2014
Same author

Sdz asm 981.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Levosalbutamol.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombolytic Therapy

Background:

  • Acute myocardial infarction (AMI) requires rapid restoration of coronary blood flow.
  • Thrombolytic agents are crucial for dissolving blood clots in AMI.
  • Alteplase is a standard thrombolytic therapy, but novel agents are being investigated.

Purpose of the Study:

  • To evaluate the efficacy and safety of lanoteplase, a recombinant plasminogen activator, in patients with acute myocardial infarction.
  • To compare lanoteplase with alteplase in terms of reperfusion rates, mortality, and adverse events.

Main Methods:

  • Phase II InTIME trial: Assessed dose-dependent reperfusion rates with lanoteplase.
  • Phase III InTIME-II study: Compared lanoteplase (120 kU/kg) with alteplase (100mg) for 30-day mortality and composite endpoints.

Related Experiment Videos

  • Analysis of TIMI flow grades, mortality, reinfarction, bleeding, heart failure, and stroke incidence.

    • Main Results:

    • Lanoteplase dose-dependently increased reperfusion rates in AMI patients.
    • Lanoteplase 120 kU/kg was superior to alteplase in achieving TIMI grade 2/3 flow at 90 minutes.
    • Preliminary InTIME-II results indicated lanoteplase was as effective as alteplase in decreasing 30-day mortality, with a lower composite incidence of death, reinfarction, major bleeding, and heart failure.
    • Lanoteplase showed a higher incidence of intracranial hemorrhage and mild bleeding but similar stroke rates compared to alteplase.

    Conclusions:

    • Lanoteplase demonstrates significant thrombolytic activity and efficacy in restoring coronary blood flow in AMI.
    • Lanoteplase appears to be as effective as alteplase in reducing 30-day mortality and may offer a favorable composite endpoint profile.
    • While effective, careful monitoring for intracranial hemorrhage and bleeding is warranted with lanoteplase therapy.